Article
Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free
Neutral
0.0
−100 Bearish
0
+100 Bullish
Regeneron is the latest in a string of major drugmakers to make pricing concessions for new and existing medicines under agreements with Trump.
Actions
Pulse AI
Pulse analysis not available yet. Click "Get Pulse" above.
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.
Article Info
Sentiment Signal
Neutral
0.0
−100Neutral+100
More Like This